Latest Adaptive Biotechnologies Corporation Stories
Deal Expected to Expedite the Development and Commercialization of Immunosequencing Applications SEATTLE, Jan.
Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.
immunoSEQ(TM) Next Generation Sequencing Assay Confirms Presence of Active Immune Response in Responders Prior to Treatment SEATTLE, Nov.
First available immunosequencing Kit with validated bias control methodology to ensure data reliability SEATTLE, Nov.
Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept.
SEATTLE, July 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is
Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE,
SEATTLE, June 19, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.